The invention relates to novel farnesylated tetrahydro-naphthalenols, that inhibit HMGR activity which results in a decrease in serum total cholesterol, a decrease in LDL cholesterol levels, and inhibition of LDL oxidation. The farnesylated tetrahydro-naphthalenols of the present invention are thus useful for cholesterol/lipid lowering in cases of hypercholesterolemia, hyperlipidemia, and atherosclerosis.
该发明涉及一种新型的韦尼基化
四氢萘酚,它抑制
HMGR活性,导致血清总
胆固醇降低,LDL
胆固醇水平降低,以及抑制LDL氧化。因此,本发明的韦尼基化
四氢萘酚在高
胆固醇血症、高脂血症和动脉粥样硬化病例中用于降低
胆固醇/脂质是有用的。